GB202311622D0 - Formulation - Google Patents
FormulationInfo
- Publication number
- GB202311622D0 GB202311622D0 GBGB2311622.1A GB202311622A GB202311622D0 GB 202311622 D0 GB202311622 D0 GB 202311622D0 GB 202311622 A GB202311622 A GB 202311622A GB 202311622 D0 GB202311622 D0 GB 202311622D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2311622.1A GB202311622D0 (en) | 2023-07-28 | 2023-07-28 | Formulation |
ARP240100532A AR132044A1 (en) | 2023-03-01 | 2024-03-01 | FORMULATION |
PCT/PT2024/050010 WO2024181881A1 (en) | 2023-03-01 | 2024-03-01 | Formulation |
TW113107582A TW202502353A (en) | 2023-03-01 | 2024-03-01 | Formulation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2311622.1A GB202311622D0 (en) | 2023-07-28 | 2023-07-28 | Formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
GB202311622D0 true GB202311622D0 (en) | 2023-09-13 |
Family
ID=87929694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB2311622.1A Ceased GB202311622D0 (en) | 2023-03-01 | 2023-07-28 | Formulation |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB202311622D0 (en) |
-
2023
- 2023-07-28 GB GBGB2311622.1A patent/GB202311622D0/en not_active Ceased
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL319149A (en) | Upadacitinib formulation | |
GB202007546D0 (en) | Formulation | |
IL307849A (en) | Sotorasib formulation | |
GB202318884D0 (en) | Formulation | |
GB202316857D0 (en) | Cannabinoid-based formulation | |
GB202312814D0 (en) | Formulation | |
GB202312220D0 (en) | Formulation | |
GB202311622D0 (en) | Formulation | |
GB202311439D0 (en) | Formulation | |
IL317857A (en) | Orellanine formulation | |
GB202308224D0 (en) | Formulation | |
GB202307003D0 (en) | Cannabinoid-based formulation | |
GB202306995D0 (en) | Cannabinoid-based formulation | |
GB202306990D0 (en) | Cannabinoid-based formulation | |
GB202307002D0 (en) | Cannabinoid-based formulation | |
GB202303663D0 (en) | Aerosolisable formulation | |
GB202218160D0 (en) | Formulation | |
GB202217857D0 (en) | Formulation | |
GB202217267D0 (en) | Aerosolisable formulation | |
GB202217148D0 (en) | Formulation | |
GB202216335D0 (en) | Formulation | |
GB202213663D0 (en) | Aerosolisable formulation | |
GB202211203D0 (en) | Formulation | |
GB202209298D0 (en) | Aerosolisable formulation | |
GB202211231D0 (en) | Novel formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |